It's a disappointing setback for a drug that has received previous approvals for similar conditions.
News & Analysis: Teva Pharmaceutical Industries
Approvals were down slightly year over year.
The fourth-quarter report wasn't great, but there are signs that a turnaround is underway.
TEVA earnings call for the period ending December 31, 2019.
The company's latest financial results are sparking investor optimism.
Analysts at investment bank Raymond James theorize that the trend will continue.
Regulators are trying their best to help encourage competition, particularly in the biosimilars market.
Strapped with debt and battling legal problems, the drugmaker could well be past its heyday.
Following declines of at least 30% in 2019, these stocks now look to be bounce-back candidates.
The idea is among a set of proposals aimed at cooling healthcare costs in the state.